Beckley Psytech Acquires Eleusis Therapeutics Limited

Eli Lilly Acquires AtaiBeckley

July 17, 2026

Biotechnology

Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, plus contingent value rights worth up to an additional $2.50 per share. The acquisition, valued at approximately $2.8 billion upfront, gives Lilly AtaiBeckley’s clinical-stage neuroplastogen pipeline, including programs for treatment-resistant depression; it was completed on September 11, 2026.

XTL Biopharmaceuticals to Acquire Psyga Bio to Build Psychedelic Biotechnology Platform

April 30, 2026

Biotechnology

XTL Biopharmaceuticals has entered into a definitive share purchase agreement to acquire 100% of Psyga Bio. The deal is structured as a share exchange with no cash consideration at closing, with XTL issuing ADSs representing 40% of Psyga Bio’s issued and outstanding share capital plus milestone-based ADSs up to an additional 10%.

EQT Private Equity to Acquire Zeus Company Inc

December 18, 2023

Medical Devices

EQT Private Equity (via its EQT X fund) has entered into an agreement to acquire Zeus Company, Inc., a global leader in advanced polymer components for medical devices, from the Tourville family. EQT plans to support Zeus with investments in production capacity, R&D, and operational improvements to accelerate growth in minimally invasive medical device markets.

Beckley Waves (via NueCo Holdings PBC) Acquires Nue Life Health

October 26, 2023

Healthcare Services

Beckley Waves, a venture studio focused on building companies in the psychedelic ecosystem, has acquired the assets of Nue Life Health Inc. through a newly launched portfolio company, NueCo Holdings PBC. The acquisition will allow Beckley Waves to scale Nue Life's at-home ketamine-assisted therapy platform and expand access to underserved patients across the United States.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II (SPKB)

January 20, 2022

Healthcare Services

Eleusis, a clinical-stage life sciences company developing IV-administered psilocybin-based drug candidate ELE-Psilo, signed a definitive business combination agreement to become a public company through a merger with SPAC Silver Spike Acquisition Corp. II. The combined company is expected to apply to list on Nasdaq under the symbol “ELEU,” with the deal expected to close in the second or third quarter of 2022, subject to customary approvals and conditions.